

## RESUME

**Helmut H. Albrecht, MD, MS, FFPM**

### **PROFESSIONAL EXPERIENCE**

**Since 2014** **Chief Scientific Officer** (part-time), Alitair Pharmaceuticals, Morristown, NJ

**Since 2008** **President, H2A-Associates LLC**, Pharmaceutical Consulting: Regulatory strategy, medical affairs & clinical science supporting development of OTC & Rx drugs; Medical Monitor (mainly oncology and neurology trials); Medical Officer and Drug Safety Reviewer roles; Technology assessments; Advertising & Claims review.

**2004-2008** **Sr. Vice President, Research & Development**  
Adams Respiratory Therapeutics, Chester, NJ

**2003-2004** **Vice President, Global Clinical & Medical Development**, Novartis Consumer Health OTC Business Unit

**2000-2003** **Vice President, R&D OTC, NA**, Novartis Consumer Healthcare, Parsippany, NJ. Responsibility for all R&D functions (incl. Medical, Clinical and Regulatory, Formulations and Analytical) and projects in North America.

**1998-2000** **Medical Director, Worldwide Safety, Medical information and GI/WHC/Herbal Supplements**, SmithKline Beecham Consumer Healthcare, Parsippany, NJ

**1996 - 1998** **Medical Director, Gastrointestinal/Women's Health Care & Herbal Supplements Categories**  
SmithKline Beecham Consumer Health Care, Worldwide Clinical & Medical Affairs, Parsippany, NJ

**1994 – 1996** **Medical Director, Clinical & Medical Affairs**, Procter & Gamble Pharmaceuticals, Cincinnati, OH

**1992 – 1994** **Medical Director, Gastrointestinal Products Category**  
Regulatory & Clinical Development, Procter & Gamble OTC Health Care, Cincinnati, OH

**1988 – 1992** **Medical Director**  
Altana Inc., Melville NY, (Byk Gulden Pharma Group)

**1985 – 1988** **Regional Medical Director, International Medicine**  
Byk Gulden Pharmaceuticals, Konstanz (FRG).

**1984 – 1985** **Resident Physician, Department of Gynecology**  
City Hospital Wiesbaden, teaching hospital University Mainz, FRG

**1983 – 1984** **Scientific Assistant at the Institute of Pathology**  
Ruperto Carola University Heidelberg, Medical Center, Heidelberg.

## EDUCATION

**1995 Diploma for Pharmaceutical Medicine (Dipl. Pharm. Med.)**  
German Association of Physicians in the Pharmaceutical Industry

**1992 Advanced Certificate in Health Care Management**  
W. Averell Harriman School for Management & Policy and School of Allied Health Professions, State University of New York (SUNY) at Stony Brook, New York

**1991 Master of Science (MS) in Management & Policy**  
W. Averell Harriman School for Management and Policy,  
State University of New York (SUNY) at Stony Brook, New York  
Thesis: Positron Emission Tomography (PET) –  
Present Status and Trend Analysis

**1983 Medical Doctor (MD), Ruperto Carola University, Heidelberg, Germany**  
Dissertation (Dr. med.): Elastase-like-protease and Hepatic Dysfunction in Patients with Malignancies (magna cum laude)

**1983 Final examination and Medical Licensure (Approbation),**  
Gesundheitsbehörde Freie und Hansestadt Hamburg, FRG  
**per Directive 93/16/EC this medical license is valid in all member countries of the European Union** as certified by  
Bundesministerium für Gesundheit, Außenstelle Berlin, 10. July, 1995.

**1982- Internships:**  
**1983 Internal Medicine and Surgery, (General Hospital Hamburg-Altona),**  
Dermatology (University Hospital, Hamburg-Eppendorf, Germany)

**1981/ Clinical Rotations Abroad:**  
**1982** - Radiology, St. Bartholomew's Hospital, University of London, UK  
- Clinical Pharmacology, Children's Hospital Columbus, OH  
- Internal Medicine Practice, Columbus, Ohio, USA

**1977- Medical Schools, Universities Heidelberg & Hamburg**  
**1983**

**1976- Medical Informatics, University Heidelberg/Heilbronn (FH) College**  
**1978**

**1974 Final Exam (Abitur), Max-Planck-Gymnasium, Trier (Germany)**

## ACADEMIC AWARDS AND HONORS

**Dissertation (Dr. med. – magna cum laude):** Elastase-like-protease and Hepatic Dysfunction in Patients with Malignancies, Ruperto Carola University Heidelberg, Medical Center, Heidelberg, Germany

## **ACADEMIC APPOINTMENTS, ADVISORY BOARDS & COMMITTEES**

**World Self-Medication Industry/Global Self-Care Federation (WSMI/GSCF)**  
Delegate to ICH Pediatric Extrapolation E11A working group (2019)

**Peer Reviewer** Dove Medical Press Journals (since 2016) and JCOPDF (2019)

**Adjunct Associate Professor**, Dept. of Cellular Biology & Pharmacology, H. Wertheim College of Medicine, Florida International University (FIU), since 2014

**Industry Liaison Representative** (ILR), FDA's Gastrointestinal Drugs Advisory Committee (GIDAC): 2012 – 2015, alternate 2016-2019, current, since 2020-23.

**Scientific Advisory Board**, Suvanza Pharma USA (2011 – present)

**Scientific Advisory Board**, Global Advisors on Smokefree Policy (GASP), NJ (since 2009)

**Board Member** of the Faculty of Pharmaceutical Medicine (FFPM), Royal Colleges of Physicians (UK): 1999-2001

## **MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS**

American Gastroenterological Association (AGA); 1996-present  
New York Academy of Sciences (NYAS), 1989 - present  
Consumer Health Products Association (CHPA), RSC member since 1998

American Medical Association (AMA), 1989 - 2011

American Academy of Dermatology (AAD), 1990 - 1993

International Society for Chronobiology (ISC), 1989 – 1994

American Society for Bone Mineral Research (ASBMR); 1999-2000

American Academy of Pharmaceutical Physicians (AAPP)

Pharmaceutical Manufacturers Association (PMA), Medical Section, 1988 – 1992

Fellow to the Faculty of Pharmaceutical Medicine (FFPM), Royal Colleges of Physicians of the United Kingdom; 1996-present

## **PATENTS**

International Publication Number: WO 2011/030163 A1 (use of Guaifenesin for inhibiting Mucin secretion)

## **PUBLICATIONS**

List of Publications can be provided upon request.

Miami, FL 07/24/2025